Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer

Objective: Treatment options for metastatic castration resistant prostate cancer (mCRPC) have expanded rapidly in recent years. Given the significant economic burden, we sought perform a cost-effectiveness analysis (CEA) of the contemporary treatment paradigm for mCRPC. Methods: We devised a treatme...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Matthew E. Pollard, Alan J. Moskowitz, Michael A. Diefenbach, Simon J. Hall
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2017-01-01
Col·lecció:Asian Journal of Urology
Matèries:
Metastatic prostate cancer
Costs and cost analysis
Health expenditures
Economics
Pharmaceutical
Accés en línia:http://www.sciencedirect.com/science/article/pii/S2214388216300911
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars